Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06173570 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 428
- Enrollment target
NCT06173570 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 428 participants.
The verdict
NCT06173570, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 428 participants
- Enrollment target
Study Summary
The primary purpose of this study is to measure the effect of different daily doses of AZD0780 on Low-Density Lipoprotein (LDL-C) levels compared with placebo in participants with dyslipidemia. The effect of AZD0780 versus placebo on other lipid parameters and inflammatory markers is also investigated. The concentration of AZD0780 in blood at specific timepoints is measured, and the safety and tolerability of AZD0780 will be evaluated. There is a follow-up after end of treatment, but expanded access is not available. The primary hypothesis is that at least one of the investigated doses of AZD0780 is superior to placebo in lowering LDL-C level, in percent change from baseline up to week 12.
Interventions
- DRUG Placebo
- DRUG AZD0780
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 428 participants |
| Start Date | 2024-01-19 |
| Est. Completion | 2024-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06173570
The ClinicalTrials.gov registry entry for NCT06173570 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 428 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06173570 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06173570 about?
NCT06173570 is a clinical study titled "A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia". The primary purpose of this study is to measure the effect of different daily doses of AZD0780 on Low-Density Lipoprotein (LDL-C) levels compared with placebo in participants with dyslipidemia. The effect of AZD0780 versus placebo on other lipid parameters and inflammatory markers is also investigat...
What is the current status of trial NCT06173570?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 428 participants. The study started on 2024-01-19. Estimated completion is 2024-09-30.
What interventions are being tested in trial NCT06173570?
The interventions under investigation include: Placebo (DRUG), AZD0780 (DRUG).
Who is sponsoring clinical trial NCT06173570?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.